When Gilead's Sovaldi and AbbVie's Viekira Pak came to market, physicians had little real-world evidence for either drug on which to base their prescribing decisions. In an attempt to fill this gap and find out what happens to hepatitis C patients between physician visits, Boston Children's Hospital has created an app for Apple ResearchKit.
The European Medicines Agency is moving toward approving a trio of novel medicines from Roche, Boehringer Ingelheim and Gilead Sciences, handing down positive recommendations for each.
Gilead Sciences has been working hard to build momentum for its cancer fighter Zydelig (idealisib), and fortunately for the company, a pricing setback in Germany didn't signal disaster elsewhere. After some initial skepticism--and a discount offer from Gilead--the U.K.'s influential cost watchdog gave its thumbs-up to the drug for chronic lymphocytic leukemia (CLL).
When Gilead laid out the terms for raising $10 billion yesterday, on top of the blockbuster money it earns on HIV and its hepatitis C drugs acquired in its buyout of Pharmasset, the move immediately stirred fresh buzz about what Gilead was going to buy next, and for how much.
Gilead Sciences is in talks with China on pricing for Sovaldi as the country stands outside of an access program by the U.S. drugmaker that relies heavily on licensing to India-based companies with the discusssions held against a backdrop of China seeking to expand insurance access for serious illness coverage.
Drugmakers are ready to pounce on Japan's rapidly growing pharmaceutical market, and Sanofi and Gilead are hopping on the bandwagon with a fresh crop of approvals. Sanofi got a regulatory OK for diabetes newcomer Toujeo, while Gilead got a greenlight for hep C combo med Harvoni in the country.
We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.
China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.
The company at the top of Fortune's fastest-growing-in-pharma list is just the one you'd expect: Gilead Sciences, with its hep C-fueled leap into the industry's top 10 by revenue. And it's no surprise that the next two are Big Biotech companies, given the ascendance of biologic meds. But one Big Pharma--and only one--managed to crack the top 5.
Gilead Sciences and AbbVie are quick to tout the efficacy of their hep C meds. Now, those numbers have helped the drugmakers score a win in the U.K. as the country's National Health Service (NHS) will spend £190 million ($294 million) for new treatments for the disease, including AbbVie's interferon-free treatment and Gilead's blockbuster hep C therapies.